FDA grants Priority Review to ocriplasmin BLA

FDA accepted and granted Priority Review to a BLA from ThromboGenics N.V. (Euronext:THR) for ocriplasmin to treat symptomatic vitreomacular adhesion. The agency's Dermatologic and Ophthalmic Drugs Adv...